Health Law & Business News
June 29, 2020, 7:38 PM
Merck’s Keytruda for intravenous injection was approved for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer, the U.S. Food and Drug Administration said in an emailed statement.
- It’s the first immunotherapy approved for this patient population as a first-line treatment and which is administered to patients without also giving chemotherapy
To contact the reporter on this story:
To contact the editor responsible for this story:
© 2020 Bloomberg L.P. All rights reserved. Used with permission.